Stifel lowered the firm’s price target on Inspire Medical (INSP) to $70 from $85 and keeps a Buy rating on the shares. The firm’s checks “highlight there is (eventually) a lot to like for Inspire Medical,” but in the near-term, the firm’s checks also suggest the Q1 reimbursement environment weighed on HGNS volumes, says the analyst, who expects these issues to impact Q1 results and takes a more conservative 2026 view.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $62 from $85 at Evercore ISI
- CMS update ‘directionally positive’ for Inspire Medical, says KeyBanc
- Inspire reimbursement unchanged as CMS confirms APC 5465 mapping, says Stifel
- Inspire Medical price target lowered to $85 from $95 at Stifel
- Inspire Medical jumps after KeyBanc says CMS ‘appears ready’ to add C-codes